Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Intravenous (IV) Ibuprofen Industry By The Forecast Year 2029?
The market for intravenous (iv) ibuprofen has experienced swift expansion recently. This market is projected to expand from $8.35 billion in 2024 to $9.37 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. This historical growth is linked to factors such as the rising incidence of chronic diseases, more frequent surgical procedures, an increasing focus on reducing opioid reliance, higher per capita income, and the expansion of medical tourism.
The intravenous (iv) ibuprofen market is set for significant expansion over the next few years, projected to reach $14.72 billion by 2029, with an impressive compound annual growth rate (CAGR) of 11.9%. This anticipated increase during the forecast period can be attributed to factors such as escalating healthcare investments, a growing population of pediatric patients, the rising prevalence of pain and fever conditions, an expanding geriatric demographic, and the increasing adoption of advanced pharmaceutical treatments. Important trends during this period are expected to encompass advanced therapeutic solutions, the development of single-dose formulations, progress in personalized medicine, the integration into multimodal pain management protocols, and advancements in combination therapies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23429&type=smp
Which Factors And Drivers Are Influencing The Intravenous (IV) Ibuprofen Market In 2025?
The increasing occurrence of pain disorders is anticipated to drive the expansion of the intravenous ibuprofen market in the future. Pain disorders are defined as medical conditions marked by persistent or chronic pain that interferes with daily functioning, often originating from nerve, musculoskeletal, or inflammatory issues. The heightened prevalence of these disorders is linked to the aging population, as older adults are more prone to developing chronic conditions such as arthritis, osteoarthritis, and nerve pain, thereby increasing the requirement for effective pain relief. Intravenous ibuprofen assists in pain management by offering quick relief, making it well-suited for acute and postoperative pain. It also works to reduce inflammation and improve patient comfort, which enhances treatment effectiveness in medical settings. For instance, in January 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, the percentage of individuals aged 16 and older who self-reported having a long-term musculoskeletal condition rose to 18.4% in 2023, up from 17.6% in 2022. Consequently, the rising prevalence of pain disorders is stimulating the growth of the intravenous ibuprofen market.
What Are The Segment Types Shaping The Intravenous (IV) Ibuprofen Market?
The intravenous (iv) ibuprofenmarket covered in this report is segmented –
1) By Product Type: Conventional Intravenous (IV) Ibuprofen; High-Concentration Intravenous (IV) Ibuprofen
2) By Strength: 100 Milligrams (mg); 200 Milligrams (mg); 400 Milligrams (mg); 800 Milligrams (mg)
3) By Age Group: Pediatrics; Adults
4) By Application: Pain; Fever; Inflammation; Other Applications
5) By End-User: Hospitals; Ambulatory Surgical Centers; Clinics; Other End-Users
Subsegments:
1) By Conventional Intravenous (IV) Ibuprofen: Pediatric Intravenous (IV) Ibuprofen; Adult Intravenous (IV) Ibuprofen
2) By High-Concentration Intravenous (IV) Ibuprofen: Single-Dose Vial; Multi-Dose Vial
Which Ongoing Trends Are Expected To Shape The Intravenous (IV) Ibuprofen Market Outlook?
Leading companies in the intravenous ibuprofen market are concentrating on developing advanced drug formulations, such as opioid-free analgesics, to improve pain management while reducing opioid dependency. An opioid-free analgesic is a pain-relieving medication that does not contain opioids, thus avoiding the risk of addiction and opioid-related side effects. For instance, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced COMBOGESIC IV (an acetaminophen and ibuprofen) injection in the US, following its Food and Drug Administration (FDA) approval in October 2023. This intravenous, opioid-free analgesic is prescribed for mild to moderate pain relief and as an adjunctive treatment for moderate to severe pain management. By combining two active ingredients with distinct mechanisms, COMBOGESIC IV offers a novel, non-opioid pain management choice for healthcare providers.
Who Are The Primary Competitors In The Global Intravenous (IV) Ibuprofen Market?
Major companies operating in the intravenous (IV) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Grifols S.A., Dr. Reddy’s Laboratories, Hikma Pharmaceuticals plc, CSL Limited, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Recordati Rare Diseases Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, Hyloris Pharmaceuticals SA
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/intravenous-iv-ibuprofen-global-market-report
What Are The Key Regional Factors Influencing The Intravenous (IV) Ibuprofen Market Growth?
North America was the largest region in the intravenous (IV) ibuprofen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (IV) ibuprofen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Intravenous (IV) Ibuprofen Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23429&type=smp
Browse Through More Reports Similar to the Global Intravenous (IV) Ibuprofen Market 2025, By The Business Research Company
Intravenous Infusion Pumps Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/intravenous-infusion-pumps-global-market-report
Intravenous Immunoglobulin Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Intravenous Iv Hydration Therapy Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model